Xiumei Dai

机构：Xuzhou Central Hospital · ORCID：0000-0002-2904-8249

发表论文 11 篇 · 总被引 48 次 · h-index 4

代表论文

• Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial (2023 · Journal of Thoracic Oncology · 被引 16)
• Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study (2024 · Journal of Clinical Oncology · 被引 13)
• Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial (2023 · BioDrugs · 被引 11)
• Survival among patients with composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A population-based study (2021 · Leukemia Research · 被引 4)
• A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors (2025 · Journal of bone oncology · 被引 2)
• Safety and preliminary efficacy of YK-029A, a novel EGFR TKI, in patients with advanced NSCLC harboring ex20ins, T790M or rare mutations. (2023 · Journal of Clinical Oncology · 被引 2)